Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CRISPR Therapeutics AG's Enterprise Value is $3,099.9 Mil.
CRISPR Therapeutics AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-222.5 Mil. Therefore, CRISPR Therapeutics AG's EV-to-EBIT ratio for today is -13.93.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, CRISPR Therapeutics AG's Enterprise Value is $3,099.9 Mil.
CRISPR Therapeutics AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-202.7 Mil. Therefore, CRISPR Therapeutics AG's EV-to-EBITDA ratio for today is -15.29.
CRISPR Therapeutics AG Enterprise Value Historical Data
The historical data trend for CRISPR Therapeutics AG's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CRISPR Therapeutics AG's Enterprise Value
For the Biotechnology subindustry, CRISPR Therapeutics AG's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Enterprise Value distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's Enterprise Value falls into.
CRISPR Therapeutics AG Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
CRISPR Therapeutics AG's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG (NAS:CRSP) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
CRISPR Therapeutics AG's current Enterprise Value is $3,099.9 Mil.
CRISPR Therapeutics AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-222.5 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
CRISPR Therapeutics AG's EV-to-EBITDA for today is:
CRISPR Therapeutics AG's current Enterprise Value is $3,099.9 Mil.
CRISPR Therapeutics AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-202.7 Mil.
CRISPR Therapeutics AG's current Enterprise Value is $3,099.9 Mil.
CRISPR Therapeutics AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $370.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG Enterprise Value Related Terms
Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
CRISPR Therapeutics AG (CRISPR Therapeutics AG) Business Description
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRSP has been successfully added to your 